SAB Biotherapeutics, Inc. Warrant financials
$0.0140−4.10%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $1.3M | $2.2M | $23.9M | $60.9M |
| Gross profit | $0.00 | $1.3M | $2.2M | $23.9M | $60.9M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | -$13.4M |
| Net income | $4.3M | -$34.1M | -$42.2M | -$18.7M | -$17.1M |
| Net margin | — | −2579.0% | −1884.5% | −78.4% | −28.2% |
| Diluted EPS | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-6.30 |
| EBITDA | -$45.9M | -$38.1M | -$34.3M | -$25.6M | -$11.9M |
| Operating cash flow | -$44.8M | -$34.3M | -$25.1M | -$23.5M | $2.0M |
| Free cash flow | -$45.7M | -$34.6M | -$25.3M | -$25.6M | -$9.0M |
| Diluted shares | 61.3M | 9.3M | 5.5M | 4.4M | 2.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $10.5M | $8.9M | $56.6M | $15.0M | $33.2M |
| Short-term investments | $86.1M | $11.9M | $0.00 | $0.00 | — |
| Total debt | $3.3M | $3.7M | $4.6M | $5.1M | $5.7M |
| Total assets | $172.8M | $44.2M | $83.9M | $50.9M | $81.1M |
| Total liabilities | $21.3M | $18.2M | $26.6M | $19.8M | $42.6M |
| Shareholders' equity | $151.5M | $26.0M | $57.3M | $31.1M | $38.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology